vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and HomeTrust Bancshares, Inc. (HTB). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $53.6M, roughly 1.4× HomeTrust Bancshares, Inc.). On growth, HomeTrust Bancshares, Inc. posted the faster year-over-year revenue change (3.7% vs -6.2%). HomeTrust Bancshares, Inc. produced more free cash flow last quarter ($45.3M vs $9.6M). Over the past eight quarters, HomeTrust Bancshares, Inc.'s revenue compounded faster (3.5% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

HomeTrust Bancshares Inc. is an Asheville, North Carolina–based bank holding company with $4.3 billion in assets and 33 branches in North and South Carolina, Georgia and Tennessee. It is the parent of seven community banks—HomeTrust Bank, Tryon Federal Bank, Shelby Savings Bank, Home Savings Bank, Industrial Federal Bank, Cherryville Federal Bank and Rutherford County Bank.

HCAT vs HTB — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.4× larger
HCAT
$74.7M
$53.6M
HTB
Growing faster (revenue YoY)
HTB
HTB
+9.9% gap
HTB
3.7%
-6.2%
HCAT
More free cash flow
HTB
HTB
$35.7M more FCF
HTB
$45.3M
$9.6M
HCAT
Faster 2-yr revenue CAGR
HTB
HTB
Annualised
HTB
3.5%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCAT
HCAT
HTB
HTB
Revenue
$74.7M
$53.6M
Net Profit
$-91.0M
Gross Margin
Operating Margin
-115.3%
37.0%
Net Margin
-121.9%
Revenue YoY
-6.2%
3.7%
Net Profit YoY
-340.3%
EPS (diluted)
$-1.29
$0.93

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
HTB
HTB
Q4 25
$74.7M
$53.6M
Q3 25
$76.3M
$54.1M
Q2 25
$80.7M
$54.4M
Q1 25
$79.4M
$50.9M
Q4 24
$79.6M
$51.7M
Q3 24
$76.4M
$50.6M
Q2 24
$75.9M
$50.6M
Q1 24
$74.7M
$50.0M
Net Profit
HCAT
HCAT
HTB
HTB
Q4 25
$-91.0M
Q3 25
$-22.2M
$16.5M
Q2 25
$-41.0M
$17.2M
Q1 25
$-23.7M
$14.5M
Q4 24
$-20.7M
Q3 24
$-14.7M
$13.1M
Q2 24
$-13.5M
$12.4M
Q1 24
$-20.6M
$15.1M
Gross Margin
HCAT
HCAT
HTB
HTB
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
HCAT
HCAT
HTB
HTB
Q4 25
-115.3%
37.0%
Q3 25
-22.9%
38.5%
Q2 25
-46.0%
40.1%
Q1 25
-25.4%
36.2%
Q4 24
-22.0%
35.4%
Q3 24
-17.9%
33.2%
Q2 24
-20.8%
31.3%
Q1 24
-30.5%
38.0%
Net Margin
HCAT
HCAT
HTB
HTB
Q4 25
-121.9%
Q3 25
-29.1%
30.5%
Q2 25
-50.8%
31.6%
Q1 25
-29.9%
28.5%
Q4 24
-26.0%
Q3 24
-19.3%
25.9%
Q2 24
-17.8%
24.6%
Q1 24
-27.6%
30.1%
EPS (diluted)
HCAT
HCAT
HTB
HTB
Q4 25
$-1.29
$0.93
Q3 25
$-0.32
$0.95
Q2 25
$-0.59
$1.00
Q1 25
$-0.35
$0.84
Q4 24
$-0.33
$0.83
Q3 24
$-0.24
$0.76
Q2 24
$-0.23
$0.73
Q1 24
$-0.35
$0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
HTB
HTB
Cash + ST InvestmentsLiquidity on hand
$95.7M
$324.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$600.7M
Total Assets
$502.6M
$4.5B
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
HTB
HTB
Q4 25
$95.7M
$324.7M
Q3 25
$91.5M
$315.8M
Q2 25
$97.3M
$297.2M
Q1 25
$342.0M
$299.8M
Q4 24
$392.0M
$279.2M
Q3 24
$387.3M
$293.5M
Q2 24
$308.3M
$294.2M
Q1 24
$327.8M
$380.5M
Total Debt
HCAT
HCAT
HTB
HTB
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
HCAT
HCAT
HTB
HTB
Q4 25
$245.8M
$600.7M
Q3 25
$331.9M
$595.8M
Q2 25
$347.5M
$579.3M
Q1 25
$376.8M
$565.4M
Q4 24
$365.2M
$551.8M
Q3 24
$355.0M
$540.0M
Q2 24
$357.0M
$523.6M
Q1 24
$357.2M
$513.2M
Total Assets
HCAT
HCAT
HTB
HTB
Q4 25
$502.6M
$4.5B
Q3 25
$587.1M
$4.6B
Q2 25
$616.2M
$4.6B
Q1 25
$891.5M
$4.6B
Q4 24
$858.9M
$4.6B
Q3 24
$813.0M
$4.6B
Q2 24
$691.7M
$4.7B
Q1 24
$695.1M
$4.7B
Debt / Equity
HCAT
HCAT
HTB
HTB
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
HTB
HTB
Operating Cash FlowLast quarter
$9.9M
$49.5M
Free Cash FlowOCF − Capex
$9.6M
$45.3M
FCF MarginFCF / Revenue
12.9%
84.5%
Capex IntensityCapex / Revenue
0.4%
7.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$93.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
HTB
HTB
Q4 25
$9.9M
$49.5M
Q3 25
$-464.0K
$-11.3M
Q2 25
$-9.0M
$-8.8M
Q1 25
$280.0K
$71.7M
Q4 24
$-3.5M
$45.4M
Q3 24
$6.2M
$43.8M
Q2 24
$1.6M
$5.9M
Q1 24
$10.3M
$-9.0M
Free Cash Flow
HCAT
HCAT
HTB
HTB
Q4 25
$9.6M
$45.3M
Q3 25
$-719.0K
$-12.0M
Q2 25
$-9.2M
$-10.2M
Q1 25
$-390.0K
$70.7M
Q4 24
$-3.9M
$42.4M
Q3 24
$5.5M
$43.1M
Q2 24
$1.3M
$5.7M
Q1 24
$10.1M
$-9.6M
FCF Margin
HCAT
HCAT
HTB
HTB
Q4 25
12.9%
84.5%
Q3 25
-0.9%
-22.2%
Q2 25
-11.4%
-18.7%
Q1 25
-0.5%
138.7%
Q4 24
-4.9%
82.0%
Q3 24
7.2%
85.1%
Q2 24
1.7%
11.2%
Q1 24
13.5%
-19.2%
Capex Intensity
HCAT
HCAT
HTB
HTB
Q4 25
0.4%
7.8%
Q3 25
0.3%
1.4%
Q2 25
0.3%
2.5%
Q1 25
0.8%
2.0%
Q4 24
0.5%
5.9%
Q3 24
0.9%
1.3%
Q2 24
0.4%
0.5%
Q1 24
0.3%
1.1%
Cash Conversion
HCAT
HCAT
HTB
HTB
Q4 25
Q3 25
-0.68×
Q2 25
-0.51×
Q1 25
4.93×
Q4 24
Q3 24
3.34×
Q2 24
0.48×
Q1 24
-0.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

HTB
HTB

Segment breakdown not available.

Related Comparisons